{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:27:56Z","timestamp":1793852876958,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["R01 HL159156"],"award-info":[{"award-number":["R01 HL159156"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL170224"],"award-info":[{"award-number":["HL170224"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL086344-15"],"award-info":[{"award-number":["5T32HL086344-15"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.athplu.2026.100615","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:56:18Z","timestamp":1790232978000},"page":"100615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Passive E06 IgG reduces lesional PC-OxPL and macrophage accumulation in cholesterol-fed Ldlr\u2212\/\u2212 mice"],"prefix":"10.1016","volume":"66","author":[{"given":"Brian","family":"Trausch-Quir\u00f3z","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Normand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuchu","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Alekseeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-2734","authenticated-orcid":false,"given":"Xiaohong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Resch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6663-1225","authenticated-orcid":false,"given":"Amir","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athplu.2026.100615_bib1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","article-title":"Oxidized phospholipids in cardiovascular disease","volume":"21","author":"Tsimikas","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.athplu.2026.100615_bib2","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100615_bib3","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100615_bib4","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","article-title":"Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes","volume":"81","author":"Gilliland","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100615_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2026.100976","article-title":"Analytical validation of monoclonal antibody-based ELISA methods for OxPL-apoB and OxPL-apo(a)","volume":"67","author":"Marcovina","year":"2026","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100615_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.126.327359","article-title":"Antibody E06 and the role of oxidized phospholipids in atherogenesis and inflammation","volume":"138","author":"Witztum","year":"2026","journal-title":"Circ Res"},{"key":"10.1016\/j.athplu.2026.100615_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1172\/JCI118853","article-title":"Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice","volume":"98","author":"Palinski","year":"1996","journal-title":"J Clin Investig"},{"key":"10.1016\/j.athplu.2026.100615_bib8","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1172\/JCI8472","article-title":"Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity","volume":"105","author":"Shaw","year":"2000","journal-title":"J Clin Investig"},{"key":"10.1016\/j.athplu.2026.100615_bib9","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1074\/jbc.M108860200","article-title":"Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation","volume":"277","author":"Friedman","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.athplu.2026.100615_bib10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nm876","article-title":"Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL","volume":"9","author":"Binder","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.athplu.2026.100615_bib11","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1194\/jlr.M400496-JLR200","article-title":"Phosphocholine as a pattern recognition ligand for CD36","volume":"46","author":"Boullier","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100615_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-018-0198-8","article-title":"Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice","volume":"558","author":"Que","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.athplu.2026.100615_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmet.2019.10.014","article-title":"Neutralization of oxidized phospholipids ameliorates Non-alcoholic steatohepatitis","volume":"31","author":"Sun","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.athplu.2026.100615_bib14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jacc.2011.07.017","article-title":"Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression","volume":"58","author":"Tsimikas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100615_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1194\/jlr.M400467-JLR200","article-title":"High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins","volume":"46","author":"Schneider","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100615_bib16","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100615_bib17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2026.100615_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0022-2275(20)33341-1","article-title":"Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice","volume":"40","author":"Zlot","year":"1999","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100615_bib19","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.jacc.2013.02.047","article-title":"Oxidation-specific biomarkers and risk of peripheral artery disease","volume":"61","author":"Bertoia","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100615_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2017.11.036","article-title":"PET\/MR imaging of malondialdehyde-acetaldehyde epitopes with a human antibody detects clinically relevant atherothrombosis","volume":"71","author":"Senders","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100615_bib21","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1194\/jlr.M025445","article-title":"Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease","volume":"53","author":"Amir","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100615_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/01.ATV.20.3.689","article-title":"In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression","volume":"20","author":"Tsimikas","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2026.100615_bib23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/hq0801.093587","article-title":"Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo","volume":"21","author":"Shaw","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2026.100615_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1161\/01.ATV.21.1.95","article-title":"Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice","volume":"21","author":"Tsimikas","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2026.100615_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/eji.1830111106","article-title":"Monoclonal vs. heterogeneous anti-H-8 antibodies in the analysis of the anti-phosphorylcholine response in BALB\/c mice","volume":"11","author":"Kearney","year":"1981","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.athplu.2026.100615_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.freeradbiomed.2025.07.042","article-title":"Valvular oxidized phospholipids correlate with severity of human aortic valvular stenosis","volume":"239","author":"Resch","year":"2025","journal-title":"Free Radic Biol Med"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089526000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089526000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:08:18Z","timestamp":1793851698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089526000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":26,"alternative-id":["S2667089526000702"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2026.100615","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Passive E06 IgG reduces lesional PC-OxPL and macrophage accumulation in cholesterol-fed Ldlr\u2212\/\u2212 mice","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2026.100615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100615"}}